INmune Bio (NASDAQ: INMB), an immunology company focused on
developing treatments that harness the patient’s innate immune system to fight
disease, this morning announced that its Director of Neuroscience, C.J. Barnum,
and Co-Founder and CEO, R.J. Tesi, M.D., will present at the 17th Annual
Congress of International Drug Discovery Science & Technology. The event,
scheduled to take place in Japan on July 26, 2019, brings together
immunotherapy industry leaders and provides a unique opportunity to connect
scientists and facilitate the exchange of ideas and developments. According to
the update, Dr. Tesi’s talk is titled, “Combination Immunotherapy to Overcome
Resistance to Cancer Treatments,” and Barnum’s presentation is titled
“Neurodegenerative Disease as an Immunological Disease: Role of Biomarkers.”
To view the full press release, visit http://ibn.fm/pqCNm
About INmune Bio Inc.
INmune Bio is a publicly traded, clinical-stage
biotechnology company developing therapies targeting the innate immune system
to fight disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
